Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381824 | 0.85 | TSHR (0.75) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL150008 | 0.85 | TSHR (0.75) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL2568978 | 0.84 | KEAP1 (0.50) | TSHRMAPK1ESR1ESR2KEAP1 | |
| SCHEMBL23935895 | 0.84 | ESR1 (0.53) | TSHRMAPK1ESR1ESR2KEAP1 | |
| SCHEMBL2941369 | 0.84 | HPGD (0.56) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL31276129 | 0.83 | HPGD (0.49) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL3442880 | 0.82 | ESR1 (0.56) | TSHRMAPK1ESR1ESR2KEAP1 | |
| SCHEMBL3442604 | 0.82 | KEAP1 (0.49) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL2571861 | 0.82 | KEAP1 (0.49) | TSHRMAPK1KEAP1HPGDTDP1 | |
| SCHEMBL4467948 | 0.82 | TSHR (0.54) | TSHRMAPK1KEAP1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115473001-B | Battery separator, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-115473001-A | Battery diaphragm, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115473001-B | Battery separator, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115473001-A | Battery diaphragm, preparation method thereof and battery | 江苏中兴派能电池有限公司 | 2022-12-13 | — | — | CN | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| CN-102532020-B | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives | REXAHN PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| WO-2008063548-A2 | 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-100390164-C | Isoquinoline compound and medical application thereof | MITSUBISHI PHARMA CORP (JP) | 2008-05-28 | — | — | CN | disclosed |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7220759-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| CN-1703410-A | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORP (JP) | 2005-11-30 | — | — | CN | disclosed |
| EP-1557414-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | TSHR 4527/4885MAPK1 849/4885ESR1 1376/4885 |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | NQO1, PARP1, PARP11 | TSHR 4858/4885MAPK1 3194/4885ESR1 4868/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | TSHR 4810/4885MAPK1 3198/4885ESR1 4751/4885 |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | NQO1, PARP1, NUDT1 | TSHR 4859/4885MAPK1 3587/4885ESR1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.